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6S Abstracts June Supplement 2014Objectives: We aimed to evaluate whether the new So-
ciety for Vascular Surgery (SVS) wound, ischemia, and foot
infection (WIfI) classiﬁcation system correlates with impor-
tant clinical outcomes for limb salvage and wound healing.
Methods: We analyzed 201 consecutive patients with
threatened limbs treated from 2010 to 2011 in an aca-
demic center. We stratiﬁed patients into clinical stages 1
to 4 based on the SVS WIfI classiﬁcation. We compared
the SVS objective performance goals of major amputation,
1-year amputation-free survival rate (AFS), and wound
healing time (WHT) according to WIfI clinical stages.
Results: Patients were a mean age of 59 years, 79%
were men, and 86% had diabetes. Forty-two patients
(21%) required major amputation, and 159 (78%) had
limb salvage. The amputation group had a signiﬁcantly
higher prevalence of advanced stage 4 patients (P <
.001), whereas the limb salvage group presented predomi-
nantly as stages 1 to 3. Patients in clinical stages 3 and 4
had a signiﬁcantly higher incidence of amputation (P <
.001), decreased AFS (P < .001), and delayed WHT
(P < .001) compared with those in stages 1 and 2. Among
patients presenting with stage 3, primarily as a result of
wound and ischemia, revascularization resulted in acceler-
ated WHT (P ¼ .008).
Conclusions: These data support the underlying
concept of the SVS WIfI classiﬁcation. As the clinical stage
progresses, the risk of major amputation increases, 1-year
AFS declines, and time to wound healing is prolonged.
We further demonstrated beneﬁt of revascularization to
improve WHT in selected patients, especially those in stage
3. Future efforts are warranted to incorporate the SVS
WIfI classiﬁcation into clinical decision-making algorithms
in conjunction with a comorbidity index and anatomic
classiﬁcation.
Table.
Amputation, 1-year AFS, Mean WHT (95% CI),
Stage No. % (n) % (n) (days)1 39 0 (0) 100 (39) 94 (69-119)
2 50 0 (0) 100 (50) 115 (92-138)
3 53 8 (4) 92 (49) 162 (105-220)
4 59 64 (38) 63 (38) 263 (167-360)AFS, Amputation-free survival; CI, conﬁdence interval; WHT, wound
healing time.
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Objectives: Endovascular aneurysm repair (EVAR) is
now a mainstay of therapy for abdominal aortic aneurysm,
although it remains associated with signiﬁcant expense. We
performed a comprehensive analysis of EVAR delivery at an
academic medical center to identify targets for qualityimprovement and cost reduction in light of impending
health care reform.
Methods: All infrarenal EVARs performed from April
2011 to March 2012 were identiﬁed (n ¼ 127). Proce-
dures were included if they met standard commercial in-
structions for use guidelines, used a single manufacturer,
and were billed to Medicare Diagnosis-Related Group
238 (n ¼ 49). Using DMAIC (deﬁne, measure, analyze,
improve, control) quality improvement methodology, tar-
gets for EVAR quality improvement were identiﬁed, and
high-yield changes were implemented. Procedure technical
costs were calculated before and after process redesign.
Results: Perioperative services and clinic visits were
identiﬁed as targets for quality improvement efforts and
cost reduction. Mean technical costs before the interven-
tion were $31,672, with endograft implants accounting
for 52%. Pricing redesign in collaboration with hospital
purchasing reduced mean EVAR technical costs to
$28,607, a 10% reduction in overall cost, with endograft
implants now accounting for 46%. Perioperative implemen-
tation of instrument tray redesign reduced instrument use
by 32% (184 vs 132 instruments), saving $50,000 annually.
Unnecessary clinic visits were reduced by 39% (1.6 vs 1.1
clinic visits per patient) through implementation of a pre-
clinic imaging protocol. There was no difference in mean
length of stay after the intervention (2.85 vs 2.45 days,
P ¼ NS).
Conclusions: Comprehensive EVAR delivery redesign
leads to cost reduction and waste elimination, while preser-
ving quality. Future efforts aimed to achieve more compet-
itive and transparent device pricing will make EVAR more
cost neutral and enhance its ﬁnancial sustainability for
healthcare systems.
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Objectives: To prospectively evaluate the neurologic
status of all patients undergoing carotid revascularization
in a single institution during a 6-year period.
Methods: Between January 2007 and June 2013, all
patients undergoing carotid revascularization underwent in-
dependent neurologic evaluation preprocedure, postproce-
dure, and at 30 days. Symptom status (symptomatic vs
asymptomatic), participation in clinical trials, stroke, death,
andmyocardial infarction (MI)were independently reviewed.
c2 Analysis and the Fisher exact test were performed.
Results: A total of 2301 interventions were per-
formed: 1969 carotid endarterectomies (CEA) 85.6% and
332 carotid angioplasty and stent procedures (CAS)
14.4%. Stroke/death/MI was 5.0%. Of 1814 patients,
